Summit Therapeutics (SMMT) Short-term Investments (2022 - 2026)

Summit Therapeutics (SMMT) has reported Short-term Investments for 5 consecutive years, with $271.3 million the latest figure, recorded in Q2 2026.

• Quarterly Short-term Investments rose 84951.1% year-over-year to $271.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $271.3 million (up 84951.1% YoY) and the FY2025 annual result came in at $488.2 million, up 58.77% from the prior year.
• Short-term Investments eased to $271.3 million in Q2 2026 per SMMT's latest filing, from $492.2 million in the prior quarter.
• Over the last five years, Short-term Investments for SMMT reached as high as $492.2 million in Q1 2026 and fell as low as $317000.0 in Q1 2024.
• A 5-year average of $170.0 million and a median of $171.9 million in 2023 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2024 — Short-term Investments plunged 99.82% — and 2026, when it soared 154684.91%.
• Year by year, Short-term Investments stood at $300.0 million in 2022, then plunged by 41.62% to $175.2 million in 2023, then soared by 75.55% to $307.5 million in 2024, then surged by 58.77% to $488.2 million in 2025, then slumped by 44.42% to $271.3 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $271.3 million, $492.2 million, and $488.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.